Darolutamide ± ADT as Neoadjuvant Therapy in High-Risk/Very High-Risk Localized Prostate Cancer

NCT07476677 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Darolutamide
DRUG: Darolutamide combined with ADT

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences